“Progression-free survival (PFS) is a surrogate endpoint widely used for overall survival (OS) in oncology.”
I feel we may have some PFS data due , very shortly for the first line head and neck data ,let’s hope it’s as favourable as the previous 2nd line head and neck data.If it is its game on , for mine.
The high overall and complete response rates for patients in Part C of the TACTI-002 trial, taken alongside their long-lasting persistence with the median Duration of Response not reached, provides a strong foundation for the ongoing TACTI-003 trial in 1st line HNSCC. The combination of the MHC Class II agonist, efti, with pembrolizumab is now showing an encouraging overall survival benefit in two different cancer indications.”As seen in multiple clinical trials, efti is generating very durable responses when combined with anti-PD-(L)1 therapies. Notably, one of the five complete responses that lasted 28 months (as of the data cut-off) occurred in a patient with negative PD-L1 expression or CPS <1
- Forums
- ASX - By Stock
- IMM
- Ann: Successful Meeting with FDA on Phase III Design in NSCLC
Ann: Successful Meeting with FDA on Phase III Design in NSCLC, page-23
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M |
Open | High | Low | Value | Volume |
41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2506 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 8079 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 62000 | 0.390 |
4 | 33064 | 0.385 |
8 | 91570 | 0.380 |
1 | 100000 | 0.370 |
4 | 24220 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.410 | 41895 | 3 |
0.415 | 130388 | 7 |
0.420 | 550003 | 10 |
0.425 | 39700 | 3 |
0.430 | 13701 | 3 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online